| Literature DB >> 30061310 |
Chih-Chun Yeh1, Ching-Jin Chang1,2, Yuh-Ching Twu3, Chen-Chung Chu4, Bi-Shan Liu1, Ji-Ting Huang1, Shu-Ting Hung1, Yung-Syu Chan5, Yi-Jui Tsai1, Sheng-Wei Lin2, Marie Lin4,5, Lung-Chih Yu1,2.
Abstract
The Xga and CD99 antigens of the human Xg blood group system show a unique and sex-specific phenotypic relationship. The phenotypic relationship is believed to result from transcriptional coregulation of the XG and CD99 genes, which span the pseudoautosomal boundary of the X and Y chromosomes. However, the molecular genetic background responsible for these blood groups has remained undetermined. During the present investigation, we initially conducted a pilot study aimed at individuals with different Xga/CD99 phenotypes; this used targeted next-generation sequencing of the genomic areas relevant to XG and CD99 This was followed by a large-scale association study that demonstrated a definite association between a single nucleotide polymorphism (SNP) rs311103 and the Xga/CD99 blood groups. The G and C genotypes of SNP rs311103 were associated with the Xg(a+)/CD99H and Xg(a-)/CD99L phenotypes, respectively. The rs311103 genomic region with the G genotype was found to have stronger transcription-enhancing activity by reporter assay, and this occurred specifically with erythroid-lineage cells. Such activity was absent when the same region with the C genotype was investigated. In silico analysis of the polymorphic rs311103 genomic regions revealed that a binding motif for members of the GATA transcription factor family was present in the rs311103[G] region. Follow-up investigations showed that the erythroid GATA1 factor is able to bind specifically to the rs311103[G] region and markedly stimulates the transcriptional activity of the rs311103[G] segment. The present findings identify the genetic basis of the erythroid-specific Xga/CD99 blood group phenotypes and reveal the molecular background of their formation.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30061310 PMCID: PMC6093725 DOI: 10.1182/bloodadvances.2018018879
Source DB: PubMed Journal: Blood Adv ISSN: 2473-9529